Sage Journals: Discover world-class research

Abstract

Background

The myeloperoxidase (MPO) -463G>A (rs2333227) polymorphism has been linked with increased susceptibility to the development of various malignancies. However, the data on the association of the MPO -463G>A transition with cervical cancer remain inconsistent.

Methods

Using high resolution melting analysis we genotyped this polymorphism in women with cervical squamous cell carcinoma (SCC) (n = 476) and controls (n = 493) from a Polish Caucasian population. Logistic regression analysis was used to adjust for the effect of confounders such as age, parity, oral contraceptive use, tobacco smoking, and menopausal status, and revealed that the MPO -463G>A single nucleotide polymorphism (SNP) was associated with an increased risk of SCC.

Results

The adjusted odds ratio (OR) for patients with the A/A genotype versus G/G genotype was 0.718 (95% CI 0.531-0.972, p = 0.0316). Stratified analyses between the MPO -463G>A polymorphism and SCC risks demonstrated a protective role of the MPO -463G>A SNP in patients with a positive history of parity and negative history of tobacco smoking. In patients with a positive history of parity, the age-adjusted OR for the A/A versus G/G genotype was 0.667 (95% CI 0.479-0.929, p = 0.0164). The age-adjusted OR for patients with a negative history of tobacco smoking for the A/A versus G/G genotype was 0.491 (95% CI 0.313-0.770, p = 0.0019).

Conclusions

Our study demonstrated that the MPO -463G>A SNP may protect from SCC in women from Polish Caucasian populations.

Keywords

Cervical carcinoma MPO Polymorphisms

Introduction

Cervical neoplasia is the second most frequent cancer in women worldwide (1). The development of this cancer is preceded by cervical intraepithelial neoplasia (CIN) (2, 3). CIN is due to infection with high-risk types of human papillomavirus (HPV) (2, 3). The majority of HPV infections are transient and do not result in the development of CIN (4, 5). It seems that the host genetic background as pertains to the host immune response is essential in the duration of HPV infection and subsequent cervical tumorigenesis (5). In addition to HPV, other factors increasing the risk of cervical tumorigenesis have been observed; these include cigarette smoking, multiparity, contraceptive use, age at time of first sexual encounter, social status, and environmental pollution (2, 6-7-8).

Myeloperoxidase (MPO) is secreted by different immune cells including neutrophils and monocytes. MPO belongs to the XPO subfamily of peroxidases, which produce chloride and hydrogen peroxide to form hypochlorous acid, a powerful oxidant (9, 10). Subsequently, hypochlorous acid and superoxide form hydroxyl radicals (11), a strong reactive radical species. MPO also produces free chlorine, which is a potent halogenating factor (12). The reactive radical species are used by neutrophils as cytotoxic agents to strike bacteria, fungi and viruses as well as malignant cells (13-14-15-16). However, the oxidative properties of the MPO-hydrogen peroxide-chloride complex can also be responsible for malignant transformation (16, 17).

The MPO gene in humans is located on chromosome 17q23 and contains many single nucleotide polymorphisms (SNPs) (18). One of these polymorphisms, MPO -463G>A (rs2333227), is related to changes in MPO production (19, 20). Moreover, increased expression of MPO has been linked with increased susceptibility to the development of various malignancies (21-22-23-24-25-26-27-28-29-30).

Higher MPO activity has been observed in gynecological cancers such as ovarian, endometrial and cervical cancer as compared to a group of healthy women (31). In contrast, decreased MPO activity has been identified in the peripheral blood neutrophils of women with cervical tumors, suggesting that women with a reduction or lack of MPO activity can be more susceptible to cervical tumor development (32). Additionally, there is inconsistent data on the MPO -463G>A polymorphism association with cervical cancer (33-34-35-36). The aim of our study was to evaluate the distribution of the MPO -463G>A transition in women with cervical cancer (n = 476) and controls (n = 493) from a Polish population.

Patients and Methods

Study Population

The study population consisted of 476 patients with cervical squamous cell carcinoma (SCC) assessed by stage and histological grade based on the International Federation of Gynecology and Obstetrics (FIGO). Patient data were provided from patients enrolled between August 2008 and December 2014 at the Department of Radiotherapy of the Greater Poland Cancer Center in Poznań, Poland (Tab. I). The control group consisted of 493 unrelated healthy female volunteers. The women with SCC and healthy female volunteers participating in the study were Caucasians from the Wielkopolska (Greater Poland) area of Poland. Informed consent was provided by all participating individuals. The study procedures were approved by the Local Ethical Committee of Poznań University of Medical Sciences.

Table I

Clinical and demographic characteristics of patients with squamous cell carcinoma and controls

Characteristic	Patients (n = 476)	Controls (n = 493)
Mean age^a (years) ± SD	52.4 ± 9.8	51.9 ± 10.2
Tumor stage
IA	66 (13.9%)
IB	64 (13.5%)
IIA	62 (13.0%)
IIB	55 (11.6%)
IIIA	153 (32.1%)
IIIB	53 (11.1%)
IVA	12 (2.5%)
IVB	11 (2.3%)
Histological grade
G1	96 (20.2%)
G2	149 (31.3%)
G3	102 (21.4%)
Gx	129 (27.1%)
Parity
Never	54 (11.3%)	55 (11.2%)
Ever	422 (88.7%)	438 (88.8%)
Oral contraceptive use
Never	259 (54.4%)	277 (56.2%)
Ever	217 (45.6%)	216 (43.8%)
Tobacco smoking
Never	308 (64.7%)	329 (66.7%)
Ever	168 (35.3%)	164 (33.3%)
Menopausal status
Premenopausal	167 (35.1%)	189 (38.3%)
Postmenopausal	309 (64.9%)	304 (61.7%)
HPV genotypes
16 and 18	321 (67.4%)
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68	362 (76.1%)

Age at first diagnosis.

Genotyping

Genotyping DNA was obtained from peripheral leukocytes using a salting out procedure. The MPO -463G>A (rs2333227) DNA fragment (132 bp) was amplified using the primers 5’ GGCTGGTCTTGAACTCCTG 3’ and 5’ GAAATCTTGGGCTGGTAGTG 3’. This polymorphism was then genotyped by high-resolution melting curve analysis (HRM) on a LightCycler 480 system (Roche Diagnostics). Of the total samples, 20% randomly selected samples were verified by a commercial sequencing service for the MPO -463G>A polymorphism.

Statistical Evaluation

The differences in genotype and allele distribution between patients and controls and their genotype deviation from the Hardy-Weinberg equilibrium were evaluated using the chi-square test. Moreover, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Unconditional logistic regression analysis was used to adjust for the effect of confounders such as age, parity, oral contraceptive use, tobacco smoking, and menopausal status. A p value of <0.05 was considered statistically significant. Statistical analysis was conducted with Statistica version 10, 2011 (StatSoft Inc.).

Results

Prevalence of the MPO -463G>A Polymorphism in Women with SCC

The distribution of the MPO -463G>A genotypes did not display significant differences from the Hardy-Weinberg equilibrium and was equal to 0.770 and 0.538 for patients and controls, respectively. The prevalence of MPO -463G>A and adjusted analyses in patients with SCC and healthy women are summarized in Table II. The MPO -463A/A genotype frequency was 1.75-fold greater in controls than cases and was 0.07 and 0.04, respectively. However, we found an almost identical frequency of the MPO -463G>A genotype in both studied groups. The MPO -463A allele frequency was slightly higher in controls than cases, namely 0.24 and 0.21, respectively. Logistic regression analysis revealed that the MPO -463A/A genotype protects against the risk of SCC. The adjusted OR for patients with the A/A versus G/G genotype was 0.718 (95% CI 0.531-0.972, p = 0.0316). However, we did not find a statistically significant association of the A allele with SCC; the adjusted OR was 0.916 (95% CI 0.771-0.916, p = 0.0732). Moreover, there was no significant association of the MPO -463G>A SNP with tumor stage and histological grade (data not shown).

Table II

Contribution of the MPO -463G>A (rs2333227) SNP to SCC

Genotype	Patients (frequency)	Controls (frequency)	Odds ratio (95% CI)	P value^a	Adjusted odds ratio (95% CI)^b	P value^a
G/G	292 (0.61)	289 (0.59)	Reference type	-	Reference type
G/A	165 (0.35)	171 (0.35)	0.955 (0.730-1.249)	0.737	0.940 (0.751-1.237)	0.695
A/A	19 (0.04)	33 (0.07)	0.5698 (0.317-1.025)	0.058	0.718 (0.531-0.972)	0.0316
MAF	0.21	0.24	0.857 (0.692-1.060)	0.154	0.916 (0.7712-0.9.160)	0.0732

Significant results are highlighted in bold.

SNP = single nucleotide polymorphism; SCC = squamous cell carcinoma; CI = confidence interval; MAF = Minor allele frequency.

Chi-square analysis.

ORs were adjusted by age, parity, oral contraceptive use, tobacco smoking, and menopausal status.

Stratified Analyses of the MPO -463G>A Polymorphism and SCC Risk

The age-adjusted assessment of the MPO -463G>A polymorphism and SCC stratified by parity, oral contraceptive use, tobacco smoking, and menopausal status are indicated in Table III. We found a protective role of the MPO -463G>A SNP in patients with a positive history of parity and a negative history of tobacco smoking. In patients with a positive history of parity, the adjusted OR for the A/A versus G/G genotype was 0.667 (95% CI 0.479-0.929, p = 0.0164). The adjusted OR for patients with a negative history of tobacco smoking for the A/A versus G/G genotype was 0.491 (95% CI 0.313-0.770, p = 0.0019). However, there was no significant correlation of the MPO -463G>A SNP with a positive history of oral contraceptive use or with menopausal status (Tab. III). Moreover, we did not find any association between the MPO -463G>A SNP and tumor stage or histological grade (data not shown).

Table III

Stratified analyses between the distribution of MPO -463G>A (rs2333227) genotypes and SCC risks: pregnancy, oral contraceptive use, tobacco smoking, and menopausal status

High risk exposure	Patients			Controls			Adjusted odds ratio (95% CI)^a	P value^c
Genotype	G/G	G/A	A/A	G/G	G/A	A/A
Parity
Ever	259	148	15	257	152	29	0.951 (0.712-1.271)	0.735^a
							0.667 (0.479-0.929)	0.0164^b
Never	33	17	4	32	19	4	0.835 (0.363-1.921)	0.668^a
							1.156 (0.523-2.556)	0.716^b
Oral contraceptive use
Ever	133	75	9	126	75	15	0.962 (0.640-1.445)	0.851^a
							0.795 (0.511-1.237)	0.308^b
Never	159	90	10	163	96	18	0.816 (0.559-1.191)	0.291^a
							0.668 (0.440-1.013)	0.0564^b
Smoking
Ever	88	68	12	96	57	11	1.302 (0.823-2.061)	0.823^a
							1.186 (0.754-1.864)	0.459^b
Never	204	97	7	193	114	22	0.723 (0.511-1.023)	0.0667^a
							0.491 (0.313-0.770)	0.0019^b
Menopausal status
Premenopausal	102	58	7	111	66	12	1.007 (0.663-1.527)	0.976^a
							0.770 (0.470-1.267)	0.304^b
Postmenopausal	190	107	12	178	105	21	0.908 (0.644-1.280)	0.582^a
							0.685 (0.469-0.999)	0.0501^b

All p values were adjusted by age. Significant results are highlighted in bold.

G/A vs. G/G.

A/A vs. G/G.

Chi-square analysis.

Discussion

The MPO gene encodes an 83-kDa precursor protein that is posttranslationally processed to form 13.5-kDa and 59-kDa subunits (37, 38). These 2 subunits are combined with heme groups to yield the tetrameric enzyme. MPO is located in the lysosomes of polymorphonuclear neutrophils and monocytes, which produce microbicidal reactive oxidants functioning as part of the innate immune system (37, 38). MPO is involved in inflammation and oxidative stress at the cellular level, which accounts for cytotoxic side effects such as damage of the DNA strand, impaired DNA repair, and tumorigenesis (17, 39-40-41). Therefore, polymorphic variants of MPO genes can be related to the development of different malignancies, including cervical cancer.

We observed that the MPO -463A/A genotype had a protective effect in patients with SCC. Moreover, we found a protective effect of the MPO -463A/A genotype in the nonsmoking subgroup and patients with a positive history of parity. In contrast to our studies, Castelão et al (33) demonstrated that women with the G/G genotype had a lower risk of invasive carcinoma. Moreover, several studies did not demonstrate the MPO -463G>A polymorphism to be a risk factor for cervical carcinogenesis. Mustea et al (36) did not find an association of the MPO -463G>A SNP with cervical cancer in 149 Caucasian patients from Moldavia including 14 cases of adenocarcinoma, 4 of adenosquamous cell carcinoma, 130 of SCC, and 1 other histological type. Nishino et al (34) also did not observe any contribution of the MPO -463G>A polymorphism to CIN 3 and invasive cervical SCC in a Japanese population. Recently, Natter et al (35) did not confirm the role of MPO -463G>A in the development of CIN 1-3 in Caucasian women.

The differences between our study, the study by Castelão et al (33) and other studies may be due to the integration of different confounding factors in our study, as well as the genetic heterogeneity between the studied populations.

To date, the MPO -463A gene variant has been recognized as a protective genetic factor in the development of various malignancies. The MPO -463G/A and A/A genotypes appear to have a reduced risk of lung, gastric and ovarian carcinoma, colorectal adenomas, and acute leukemia (21-22-23, 42, 43). The presence of the MPO -463A/A genotype was associated with a decreased risk of breast and bladder cancer (24-25-26). Patients carrying the MPO -463A-allele genotypes also displayed a decreased risk of hepatoblastoma and esophageal carcinoma (44, 45). It has also been demonstrated that there is MPO -463G/G genotype overrepresentation in patients with early stage ovarian, prostate and hepatocellular carcinoma, as well as chronic lymphocytic leukemia and multiple myeloma (27-28-29-30).

The role of the MPO -463G>A transition in the expression of MPO has been documented in several studies. The MPO -463G variant contains the SP1 binding site, which activates transcription by 25-fold in transient transfection assays, while the MPO -463A allele results in several-fold less transcriptional activity (19). Reynolds et al (20) confirmed that the MPO -463G allele forms the SP1 and retinoic acid response element located in the MPO promoter. Moreover, they found that the MPO -463G/G genotype was linked to elevated MPO mRNA levels in primary myeloid leukemia cells (18, 19). In addition to these findings, Saygili et al (27) demonstrated that patients with chronic lymphocytic leukemia and multiple myeloma and the MPO -463G/G genotype had elevated serum MPO levels.

In the present study, the protective role of the MPO -463A/A genotype in cervical carcinogenesis in nonsmoker patients and patients with a positive history of parity may also be related to a lower MPO activity, which reduced DNA damage and carcinogenesis. In contrast, in the smoker group we observed no effect of the MPO -463A/A genotype, which may be due to the strong carcinogenic effect of cigarette components and the MPO -463G/G genotype. The lack of the MPO -463A/A genotype's protective effect in patients with no parity, menopausal status, and a history of contraceptive use can be due to this patient group having a large number of smokers.

We are the first to demonstrate that the MPO -463G>A SNP may protect from cervical SCC in women who are nonsmokers and have had children and are from a Polish Caucasian population; this study should be repeated in other independent ethnicities.

Footnotes

Acknowledgment

The technical assistance of Ms. Agnieszka Hertel is gratefully acknowledged.

Financial support: Supported by grant no. 502-01-01124182-07474 from Poznań University of Medical Sciences.

Conflict of interest: There are no conflicts of interest related to this study.

References

Jemal

Bray

Center

Ferlay

Ward

Forman

Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90

Schiffman

Bauer

Hoover

. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85(12):958–964

de Villiers

Wagner

Schneider

. Human papillomavirus infections in women with and without abnormal cervical cytology. Lancet 1987;2(8561):703–706

de Freitas

Gurgel

Chagas

Coimbra

do Amaral

Susceptibility to cervical cancer: an overview. Gynecol Oncol 2012;126(2):304–311

Magnusson

Lichtenstein

Gyllensten

Heritability of cervical tumours. Int J Cancer 2000;88(5):698–701

Kasap

Yetimalar

Keklik

Yildiz

Cukurova

Soylu

Prevalence and risk factors for human papillomavirus DNA in cervical cytology. Eur J Obstet Gynecol Reprod Biol 2011;159(1):168–171

Appleby

Beral

Berrington de González

et al; International Collaboration of Epidemiological Studies of Cervical Cancer. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007;370(9599):1609–1621

Castellsagué

Muñoz

Chapter 3: Cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003;2003(31):20–28

Klebanoff

Myeloperoxidase-halide-hydrogen peroxide antibacterial system. J Bacteriol 1968;95(6):2131–2138

10.

Klebanoff

Coombs

Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system. J Clin Invest 1992;89(6):2014–2017

11.

Ramos

Pou

Britigan

Cohen

Rosen

Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. J Biol Chem 1992;267(12):8307–8312

12.

Hazen

Hsu

Duffin

Heinecke

Molecular chlorine generated by the myeloperoxidase-hydrogen peroxide-chloride system of phagocytes converts low density lipoprotein cholesterol into a family of chlorinated sterols. J Biol Chem 1996;271(38):23080–23088

13.

Klebanoff

Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980;93(3):480–489

14.

Clark

Klebanoff

Einstein

Fefer

Peroxidase-H2O2-halide system: Cytotoxic effect on mammalian tumor cells. Blood 1975;45(2):161–170

15.

Clark

Klebanoff

Neutrophil-mediated tumor cell cytotoxicity: role of the peroxidase system. J Exp Med 1975;141(6):1442–1447

16.

Trush

Seed

Kensler

Oxidant-dependent metabolic activation of polycyclic aromatic hydrocarbons by phorbol ester-stimulated human polymorphonuclear leukocytes: possible link between inflammation and cancer. Proc Natl Acad Sci USA 1985;82(15):5194–5198

17.

Van Rensburg

Van Staden

Anderson

Van Rensburg

Hypochlorous acid potentiates hydrogen peroxide-mediated DNA-strand breaks in human mononuclear leucocytes. Mutat Res 1992;265(2):255–261

18.

Nauseef

Aberrant restriction endonuclease digests of DNA from subjects with hereditary myeloperoxidase deficiency. Blood 1989;73(1):290–295

19.

Piedrafita

Molander

Vansant

Orlova

Pfahl

Reynolds

An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 1996;271(24):14412–14420

20.

Reynolds

Chang

Douer

Ball

Kanda

An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 1997;90(7):2730–2737

21.

Zhou

Luo

Qing

Lin

Zhan

Ouyang

Association between MPO 463G>A polymorphism and risk of lung cancer: a meta-analysis. Tumour Biol 2013;34(6):3449–3455

22.

Jiang

Zhang

Wang

. Association of the 463G-A myeloperoxidase gene polymorphism with gastric cancer risk. Hepatogastroenterology 2012;59(115):757–761

23.

Olson

Carlson

Ostrer

. Genetic variants in SOD2, MPO, and NQO1, and risk of ovarian cancer. Gynecol Oncol 2004;93(3):615–620

24.

Qin

Deng

Zeng

. Myeloperoxidase polymorphism, menopausal status, and breast cancer risk: an update meta-analysis. PLoS ONE 2013;8(8):e72583

25.

Pabalan

Jarjanazi

Sung

Ozcelik

Menopausal status modifies breast cancer risk associated with the myeloperoxidase (MPO) G463A polymorphism in Caucasian women: a meta-analysis. PLoS ONE 2012;7(3):e32389

26.

Hung

Boffetta

Brennan

. Genetic polymorphisms of MPO, COMT, MnSOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 2004;25(6):973–978

27.

Saygili

Aksoy

Pehlivan

. Enzyme levels and G-463A polymorphism of myeloperoxidase in chronic lymphocytic leukemia and multiple myeloma. Leuk Lymphoma 2009;50(12):2030–2037

28.

Castillo-Tong

Pils

Heinze

. Association of myeloperoxidase with ovarian cancer. Tumour Biol 2014;35(1):141–148

29.

Tefik

Kucukgergin

Sanli

Oktar

Seckin

Ozsoy

Manganese superoxide dismutase Ile58Thr, catalase C-262T and myeloperoxidase G-463A gene polymorphisms in patients with prostate cancer: relation to advanced and metastatic disease. BJU Int 2013;112(4):E406–E414

30.

Nahon

Sutton

Rufat

. A variant in myeloperoxidase promoter hastens the emergence of hepatocellular carcinoma in patients with HCV-related cirrhosis. J Hepatol 2012;56(2):426–432

31.

Song

Santanam

Increased myeloperoxidase and lipid peroxide-modified protein in gynecological malignancies. Antioxid Redox Signal 2001;3(6):1139–1146

32.

Blicharski

Wolska

Zduńczyk

. Enzymes of neutrophils in women with malignant tumors of reproductive organs. Folia Histochem Cytochem (Krakow) 1980;18(3):173–182

33.

Castelão

da Silva

Matos

. Association of myeloperoxidase polymorphism (G463A) with cervix cancer. Mol Cell Biochem 2015;404(1-2):1–4

34.

Nishino

Sekine

Kodama

. Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res 2008;34(6):994–1001

35.

Natter

Polterauer

Pils

. Association of -463G/A MPO gene polymorphism and risk of cervical intraepithelial neoplasia. Arch Gynecol Obstet 2016;293(4):865–869

36.

Mustea

Heinze

Sehouli

. The -463G/A polymorphism in myeloperoxidase gene and cervical cancer. Anticancer Res 2007;27(3B):1531–1535

37.

Yamada

Kurahashi

Regulation of myeloperoxidase gene expression during differentiation of human myeloid leukemia HL-60 cells. J Biol Chem 1984;259(5):3021–3025

38.

Klebanoff

Myeloperoxidase. Proc Assoc Am Physicians 1999;111(5):383–389

39.

Petruska

Mosebrook

Jakab

Trush

Myeloperoxidase-enhanced formation of (+-)-trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene-DNA adducts in lung tissue in vitro: a role of pulmonary inflammation in the bioactivation of a procarcinogen. Carcinogenesis 1992;13(7):1075–1081

40.

Josephy

The role of peroxidase-catalyzed activation of aromatic amines in breast cancer. Mutagenesis 1996;11(1):3–7

41.

Pero

Sheng

Olsson

Bryngelsson

Lund-Pero

Hypochlorous acid/N-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis 1996;17(1):13–18

42.

Qin

Wang

Zhu

Huang

The myeloperoxidase-463 G>A polymorphism influences risk of colorectal cancer in southern China: a case-control study. Asian Pac J Cancer Prev 2011;12(7):1789–1793

43.

Zhang

Zhu

. Analysis of multiple single nucleotide polymorphisms (SNPs) of myeloperoxidase (MPO) to screen for genetic markers associated with acute leukemia in Chinese Han population. J Toxicol Environ Health A 2007;70(11):901–907

44.

Pakakasama

Chen

Frawley

Muller

Douglass

Tomlinson

Myeloperoxidase promotor polymorphism and risk of hepatoblastoma. Int J Cancer 2003;106(2):205–207

45.

Matsuo

Hamajima

Shinoda

. Possible risk reduction in esophageal cancer associated with MPO -463 A allele. J Epidemiol 2001;11(3):109–114

Involvement of Myeloperoxidase Gene Polymorphism 463G>A in Development of Cervical Squamous Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keywords

Introduction

Patients and Methods

Study Population

Genotyping

Statistical Evaluation

Results

Prevalence of the MPO -463G>A Polymorphism in Women with SCC

Stratified Analyses of the MPO -463G>A Polymorphism and SCC Risk

Discussion

Footnotes

Acknowledgment

References